Bioverativ Inc Stock

Stocks

27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
15/02/18	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
23/01/18	Stocks hit record as senators reach deal to end shutdown	RE
22/01/18	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
22/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
22/01/18	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

06/03/18	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
14/02/18	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
14/02/18	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
24/01/18	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
24/01/18	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

29/03/18	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
08/03/18	Sanofi finalise l'acquisition de Bioverativ
08/03/18	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
23/02/18	Sanofi : franchit une étape dans son offre sur Bioverativ
07/02/18	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy Harris PRN	Corporate Officer/Principal	76	01/02/2017
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	08/03/2018
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+42.79%	+64.16%	65B
ARGENX SE	-4.09%	-0.11%	+2.31%	+54.81%	51.19B
LONZA GROUP AG	+0.03%	+5.56%	+10.18%	+41.75%	51.2B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+29.72%	+34.13%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.05%	+112.18%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+258.21%	+421.57%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+15.74%	+53.94%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+31.48%	-1.63%	25.2B
BIONTECH SE	-2.76%	-9.54%	-16.53%	-9.55%	22.03B
Average	-1.66%	-1.67%	+43.33%	+85.71%	41.32B
Weighted average by Cap.	-2.30%	-1.21%	+43.56%	+88.58%

Employees

Sector